Jpn J Pharmacol data (2002”N6ŒŽ30“úŒ»ÝƒQƒ“ƒUƒC)
@ “àƒEƒ` ŠCŠOƒJƒCƒKƒC
˜_•¶R¸Œ‹‰Ê @@@@@@@@@@@@@@@@@ “Še˜_•¶‚Ì•ª–ì (œ Review)@@@@@ @ @
@ 1999 2000 2001 Jun-02 @ @ 1999 2000 2001 Jun-02 @
Žó— 180 21 186 25 188 26 84 16 @ 1.¶—Šˆ«•¨Ž¿ 5 2 7 3 7 @ 2 1 @
Reject 24 7 24 12 41 16 18 11 @ ‚Q.Žó—e‘́Eƒ`ƒƒƒlƒ‹E—A‘—Œn 12 1 14 1 20 3 5 1 @
Žæ‰º‚° 24 4 12 2 20 4 11 2 @ ‚R.×–E“àî•ñ“`’B 4 @ 6 1 2 @ 3 1 @
‡Œv 228 32 222 39 249 46 113 29 Œ ‚S.¶‰»Šw–ò— 19 6 14 5 16 4 4 4 @
Reject—¦(ŠÜ.Žæ‰º‚°) 21.1 34.4 16.2 35.9 24.5 43.5 25.7 44.8 % ‚T.––½_Œo–ò— 6 @ 9 1 10 1 9 1 @
@@ ‚U.SŒŒŠÇ–ò— 42 5 40 5 38 3 25 9 @
‚V.’†•_Œo–ò— 33 4 44 11 36 11 14 3 @
“ŠeŒ”@@@@@@@@@@@@@@@@@@@ ‚W.ŒÄ‹zŠí–ò— 8 1 8 1 6 1 1 @ @
@ 1999 2000 2001 Jun-02 @ ‚X.t–ò— 5 @ 12 1 9 @ 0 @ @
Full Paper 145 24 155 32 146 27 77 23 @ ‚P‚ODÁ‰»Ší–ò— 26 1 16 4 17 3 9 2 @
Short Commun. 51 1 64 9 54 7 21 4 @ ‚P‚PD•½ŠŠ‹Ø–ò— 6 1 13 3 6 @ 5 1 @
Rapid Commun. 1 0 8 0 3 0 1 0 @ ‚P‚QDœEŽ•‰È–ò— 7 @ 6 @ 7 @ 4 @ @
Review 22 6 24 10 35 10 5 1 @ ‚P‚RD“à•ª”å–ò— 3 1 7 @ 6 2 3 @ @
Review “à–óƒEƒ`ƒƒP [Invite R] 22 6 17 7 16 4 3 0 @ ‚P‚SD—Տ°–ò— 1 @ 2 2 4 @ 3 1 @
@@[“Še] ˆê”Ê   0 0 1 1 4 2 1 1 @ ‚P‚TD–Ɖu–ò—E‰ŠÇ 10 1 20 1 14 3 4 1 @
@@[“ŠeƒgƒEƒRƒE] F Mini R 0 0 6 2 14 4 0 0 @ ‚P‚UD‰»Šw—Ö@ 2 1 4 1 1 1 1 @ @
@@[“ŠeƒgƒEƒRƒE] New Drug 0 0 0 0 1 0 1 0 @ ‚P‚VD“ʼnȊw 8 1 5 1 4 2 7 2 @
‡Œv 219 31 251 51 238 44 104 28 Œ ‡Œv 197 25 227 41 203 34 99 27 Œ
Invite RFInvite Review, F Mini R: Forum Minireview @ @ @ @ @ @ @ @ @ @
@ 1998 1999 2000 2001 @
Impact Factor 1.533 1.21 1.317 1.347 @